News | February 19, 2022
Jagsonpal Pharma inks agreement with Suvinys Developers
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The brand has added a range of exciting new products especially formulated for oily skin.
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
ArisGlobal's industry-leading regulatory software chosen by top pharmaceutical company for IDMP preparation and global readiness
Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.
Subscribe To Our Newsletter & Stay Updated
